Drug class
Tissue factor pathway inhibitor (TFPI) monoclonal antibody; procoagulant biologic
Mechanism of action
Binds TFPI and inhibits its anticoagulant activity, increasing tissue factor-initiated thrombin generation and supporting haemostasis in haemophilia.
General use cases
- Routine prophylaxis to prevent or reduce bleeding episodes in eligible adults and adolescents aged 12 years and older with haemophilia A or B with inhibitors under the US ALHEMO indication; not for treatment of acute bleeding episodes
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
